Saint-Prex, Switzerland
Saint-Prex, Switzerland

Time filter

Source Type

MetaboGen AB and Ferring Pharmaceuticals announce a research collaboration aimed at developing a microbiome-based product to prevent and treat Intrahepatic Cholestasis of Pregnancy (ICP). In December recruitment of patients for the first clinical trial begins. MetaboGen has developed and patented a concept for how the microbiome (the overall expression of microbial genes) could affect intrahepatic cholestasis of pregnancy, a disorder affecting around 400,000 pregnant women annually. Recruitment of patients for the first clinical study begun 6 December 2016. The 18-month long study is conducted in cooperation with the Women’s Clinic in Lund, Sweden. 100 pregnant women will be included in the trial. In December 2014 BioGaia took the decision to invest SEK 12 million in MetaboGen AB, and BioGaia's Group President Peter Rothschild became Chairman of the Board of the company. The investment was to be made over a two-year period and the last of three investments was done 30 November 2016. BioGaia's share of MetaboGen today amounts to 36 percent and BioGaia has no current plans of changing this. "BioGaia's investment in MetaboGen is long term and aims at developing the next generation of probiotic products, based on in-depth analyses of the microbiome. The research field is expanding rapidly and several large pharmaceutical companies have invested in microbiome companies. We are very positive about MetaboGen’s collaboration with Ferring, which is an ideal partner for this type of product. It is also satisfying that MetaboGen already is underway with a clinical trial”, says Peter Rothschild, Group President BioGaia. What is Intrahepatic Cholestasis of Pregnancy (ICP)? Intrahepatic cholestasis of pregnancy (ICP) is a disorder that can develop in pregnancy. ICP affects about 400,000 pregnant women annually and is a recurrent disease: 70 per cent of women who have been diagnosed with ICP during their first pregnancy will be affected again in following pregnancies. In addition to itching, which may be intense and very uncomfortable for the mother, there are links between ICP and preterm birth and gestational diabetes. Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in more than 100 countries. MetaboGen is a research-driven company with a focus on the microbiome and its impact on health. The company was founded in Gothenburg, Sweden and is based on break-through science from the labs of Professor Fredrik Bäckhed (University of Gothenburg) and Professor Jens B Nielsen (Chalmers University of Technology). Since 2011, MetaboGen develops products based on advanced mapping of the intestinal microflora composition. In 2014 BioGaia AB invested in the company. MetaboGen’s technology, along with more than 25 years of experience in the development of probiotics from BioGaia, provides the company with a unique opportunity to develop the next generation of microbial products. BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 90 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of Nasdaq OMX Nordic Exchange Stockholm. biogaia.com This information was brought to you by Cision http://news.cision.com


News Article | April 20, 2016
Site: www.nature.com

Future health spend The provision of aid for global health has stagnated since the 2008 financial crisis, following years of increases during the early 2000s, and international health-spending inequalities will persist as a result, predicts a report (J. L. Dieleman et al. Lancet http://doi.org/bfdr; 2016). In a companion report, data extrapolated from health spending between 1995 and 2013 suggest that nearly half of low- and lower-middle-income countries are likely to miss an internationally agreed goal to spend at least US$86 per person on health by 2040 (J. L. Dieleman et al. Lancet http://doi.org/bfds; 2016). By that time, the wealthiest countries will spend an average of $9,019 per person on health, compared with $164 per person by the poorest countries. Earthquakes strike Ecuador and Japan A magnitude-7.8 earthquake struck Ecuador’s coast on 16 April, collapsing buildings and killing hundreds of people. The death toll was 413 as Nature went to press. It was the country’s most powerful quake since 1979 and it devastated towns near the coast. Separately, a series of shallow earthquakes shook Japan’s Kyushu island last week, culminating in a magnitude-7 tremor on 16 April that killed at least 42 people. Buildings including a student residence, as well as turrets on a seventeenth-century castle, collapsed in Kumamoto prefecture. Zika link declared The US Centers for Disease Control and Prevention (CDC) has declared that the mosquito-borne Zika virus causes microcephaly — babies born with abnormally small heads — and other fetal brain defects. The announcement, on 13 April, is based on a review of evidence by CDC researchers (see S. A. Rasmussen et al. http://doi.org/bfc2; 2016). The mosquito season in the southern US states is looming, and the agency says that strong causal messages will reinforce advice about precautions. Some scientists caution that the proof is not yet unequivocal, but that the CDC is justified in erring on the side of caution. Antarctic cruise Swiss coordinators of the planned international Antarctic Circumpolar Expedition announced on 18 April the 22 scientific projects selected to take place on the research cruise. On 20 December, a 55-strong research crew involving scientists from 30 countries will set out from Cape Town on a three-month voyage on board the Russian research vessel Akademik Treshnikov. The scientists hope to extensively probe the Southern Ocean and map unexplored biota around Antarctica. The expedition is largely funded by the Swedish philanthropist Frederik Paulsen, founder of Ferring Pharmaceuticals. Vaccine switch Between 17 April and 1 May, 155 countries will introduce a new kind of polio vaccine as part of a global push to eradicate the disease. The switch will replace a ‘trivalent’ vaccine against the three serotypes of poliovirus with a more effective vaccine that targets the two types of virus that are still circulating. Just 10 cases of polio caused by a wild virus have been reported this year, in Pakistan and Afghanistan. Whales threat Marine-mammal experts have urged US President Barack Obama to halt permits for seismic oil and gas surveys along the mid- and southeastern US Atlantic coast. Fewer than 500 North Atlantic right whales (Eubalaena glacialis, pictured) remain in the wild, 27 right-whale experts from the United States, Canada and Britain said in a 14 April letter to Obama. Noise pollution from the airgun blasts used to return information about oil and gas deposits would affect the animals on important feeding and breeding grounds, the letter says. Glyphosate rule The European Parliament has called on the European Commission to restrict its marketing authority for the widely used herbicide glyphosate to seven years, amid controversy over whether the chemical may be harmful to health. The commission had instead proposed a 15-year renewal of the authority — which expires in June — to market glyphosate in European Union member states. Parliament’s resolution on 13 April also calls for a new independent safety review and a restriction of glyphosate use in public areas. The resolution has no legal authority, but might influence a May vote by member states on the proposal. CRISPR crops The US Department of Agriculture said on 13 April that it will not regulate a mushroom genetically modified with the CRISPR–Cas9 gene-editing tool. The mushroom can now be cultivated and sold without passing through the agency’s regulatory process; it is the first CRISPR-edited organism to receive a green light from the US government (see page 293). And on 18 April, DuPont Pioneer in Johnston, Iowa, announced plans to commercialize high-starch varieties of maize (corn) that have been genetically modified with CRISPR to boost yields. The company aims to have the maize available within five years. Untested drug Brazil’s President Dilma Rousseff has signed a law allowing patients to access an untested, unapproved compound that some claim is a miracle cure for cancer. The law, which went into effect on 14 April, allows those with a certificate verifying that they have cancer to obtain the drug; no prescription is required. The news came just weeks after Brazil’s Ministry of Science, Technology and Innovation released laboratory results showing that the compound does not kill cancer cells grown in culture. See go.nature.com/gwzswx for more. Warming review The Intergovernmental Panel on Climate Change will review the possible effects on humans and ecosystems of a rise in global temperature of 1.5 °C above pre-industrial levels. At a meeting on 11–13 April in Nairobi, the group agreed to produce three special reports: one looking at the impacts of 1.5 °C of warming, with the other two assessing the impacts of climate change on land use and terrestrial ecosystems, and on oceans, glaciers and polar ice sheets. See go.nature.com/aq3yhf for more. Green light The European Space Agency’s ambitious plans to build a space-based gravitational-wave detector are feasible and the mission could launch sooner than planned, an expert panel reported on 12 April (see Nature 531, 30; 2016). The chair of the Gravitational Observatory Advisory Team, University College Dublin physicist Michael Perryman, told the BBC that the group will suggest a launch in 2029, which would bring forward the proposed start date of the €1-billion (US$1.1‑billion) mission by 5 years. Exxon sponsorship The board of the American Geophysical Union (AGU) has decided to continue to accept sponsorship money from the oil and gas giant ExxonMobil, despite a February letter from more than 170 AGU members and others complaining about the company’s past role in spreading climate misinformation. “We concluded that it is not possible for us to determine unequivocally whether ExxonMobil is participating in misinformation about science currently,” AGU president Margaret Leinen wrote in a blog post on 14 April describing the board’s vote. Last year, the AGU accepted US$35,000 in support from ExxonMobil. Cancer institute The Parker Foundation, a charity in San Francisco, California, has committed US$250 million to harnessing the immune system to fight cancer. The money will support more than 40 laboratories at 6 centres of medical research, which together will form the Parker Institute for Cancer Immunotherapy, the foundation announced on 12 April. The institute — to be led by immunologist Jeffrey Bluestone of the University of California, San Francisco — will manage any intellectual property that emerges from the collaboration. The area planted globally with genetically modified (GM) crops declined in 2015. The 1% decline — the first in the technology’s 20-year global commercial history — was primarily due to a decrease in both GM and non-GM crops caused by low prices, says the body that tracks such crops. But the International Service for the Acquisition of Agri-Biotech Applications also said in its 13 April report that major growers of GM crops, such as the United States, are approaching saturation. 21 April The United Nations hosts a high-level debate on implementing its sustainable development goals for 2030, in New York. go.nature.com/ku8o5l 22 April Sentinel-1B, a radar observation satellite developed by the European Space Agency, will launch from Sinnamary, French Guiana. go.nature.com/9pmfp7 The Paris Agreement on climate change, adopted in December, will be signed in New York. go.nature.com/7fpxfw


News Article | February 15, 2017
Site: www.businesswire.com

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute (FRI) which provides grants of up to $100,000 for early stage research. The program focuses on novel extracellular drug targets addressable with peptides or proteins within Ferring’s core therapeutic areas: reproductive health, gastroenterology, urology, and endocrinology. The 2016-2017 awardees and their research subjects are: Stuart Brierley - Flinders University, Australia Venom-derived NaV1.1 inhibitors as novel candidates for treating chronic visceral pain associated with IBS James Deane - Hudson Institute of Medical Research, Australia Investigating the requirement for Notch and Hedgehog signalling in the endometrial stem/progenitor populations that cause endometriosis Marie van Dijk - University of Amsterdam, Netherlands ELABELA as a potential biomarker and therapeutic for pre-eclampsia Florenta Kullmann - University of Pittsburgh, USA Artemin: a novel target for treatment of interstitial cystitis/bladder pain syndrome Mireille Lahoud - Monash University, Australia The development of Clec12A-ligands as a therapeutic approach to regulate gastrointestinal inflammation Padma Murthi - Monash University, Australia Investigating the role of novel peptide receptor as an effective target to improve placental function in preeclampsia Markus Muttenthaler - The University of Queensland, Australia Mapping the location and function of oxytocin and vasopressin receptors throughout the gut Rodrigo Pacheco – Fundación Ciencia & Vida and Universidad Andres Bello, Santiago, Chile Targeting heteromers formed by G-protein coupled receptors involved in the gut-homing of T-cells in inflammatory bowel diseases Aritro Sen – The University of Rochester, USA Regulation of AMH expression by GDF9+BMP15 and FSH during follicular development as a novel therapeutic option “We look forward to the outcomes of the research being carried out by our grant awardees,” said Keith James, President of FRI and Senior Vice President, Research and Development. “Ferring is committed to stimulating basic research, with the ultimate aim of developing innovative products that improve the lives of patients.” Applications for the 2017-2018 Ferring Innovation Grants programme will open in spring/summer 2017. For more information on this year’s program, visit www.ferring-research.com/ferring-grants. About Ferring Research Institute Inc Located in San Diego, California Ferring Research Institute Inc. (FRI) is the global peptide therapeutics research center for Ferring Pharmaceuticals. FRI is committed to building a portfolio of novel, innovative peptide-based drugs and biologicals to address the high unmet medical need for patients in our therapeutic areas of interest. For more detailed information please visit www.ferring-research.com. About Ferring Pharmaceuticals Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.


News Article | November 8, 2016
Site: globenewswire.com

Strategic Focus on Growing Global Vitaros® Revenue and Achieving Profitability in 2017 Apricus Granted Type B Meeting with FDA to Discuss the Vitaros® U.S. NDA Re-Submission Conference Call / Webcast Today, Tuesday, November 8, 2016 at 4:30 p.m. ET SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the third quarter of 2016 and provided a corporate update on its priorities for 2016. “In the third quarter, we focused our efforts on advancing the regulatory and commercial success of Vitaros® through our partners.  Since July, our partners have launched Vitaros in five additional countries in Europe, and received an additional five marketing authorizations for Vitaros in Europe, Latin America and the Middle East.  Further, the transfer of commercial rights to Ferring in certain countries in Europe and Asia was completed,” stated Richard W. Pascoe, Chief Executive Officer.  “Looking forward, our focus continues to be increasing Vitaros ex-U.S. revenue and obtaining the regulatory approval of Vitaros in the United States.  Our Type B meeting with the FDA, which is scheduled for November 17, 2016, remains on schedule.  The purpose of this meeting is to confirm our strategy for addressing the deficiencies contained in the original 2008 Complete Response letter. We will incorporate any FDA feedback into the final resubmission, which we expect to occur in the fourth quarter.” Apricus continued to focus its corporate goals on increasing Vitaros’ value through the fostering and expansion of its commercial partnerships, in the U.S. and globally, and strengthening the Company’s financial position.  Third quarter and recent highlights include: Apricus continues to focus on achieving the following key strategic objectives: Total revenues for the quarter and year to date period ended September 30, 2016 were $4.3 million and $5.4 million, respectively, as compared to $1.3 million and $2.2 million for the quarter and year to date period ended September 30, 2015, respectively.  The increase for both periods was primarily due to the recognition in the third quarter of 2016 of $3.9 million due to the expansion of the Company’s license agreement with Ferring.  Cost of goods sold for the quarter and year to date period ended September 30, 2016 were $0.1 million and $0.4 million, as compared to $0.1 million and $0.9 million for the quarter and year to date period ended September 30, 2015.  Cost of Sandoz rights for the quarter and year to date period ended September 30, 2016 includes $3.4 million incurred as a cost of reacquiring and relicensing the rights to certain territories previously licensed to Sandoz.  Research and development expense for the nine months ended September 30, 2016 was $6.0 million, as compared to $11.0 million for the nine months ended September 30, 2015.  The decrease was primarily due to decreased spending on outside services related to the development of fispemifene, Vitaros and RayVa.  General and administrative expense for the nine months ended September 30, 2106 was $6.5 million, as compared to $8.2 million for the nine months ended September 30, 2015.  The decrease was primarily due to lower professional services expenses, such as legal and accounting expenses, and reductions in personnel-related expenses, including travel.  Net loss for the quarter ended September 30, 2016 was $1.3 million, or loss per share of $0.19, compared to a net loss of $5.0 million, or $1.00 per share for the third quarter of 2015. Net loss for the nine months ended September 30, 2016 was  $7.1 million, or loss per share of $1.17, compared to a net loss of $16.7 million, or loss per share of $3.37 for the nine months ended September 30, 2015.  Reducing the net loss for the nine months ended September 30, 2016 was a non-cash change in the fair value of the Company’s warrant liability in the amount of $5.1 million. As of September 30, 2016, cash and cash equivalents totaled $5.6 million, compared to $3.9 million as of December 31, 2015. Early in the second quarter of 2016, Apricus reduced its staff, including the executive team, by approximately 30%, decreased the size of the Board by one member and reduced the Board’s cash compensation.  Apricus plans to continue to reduce operating expenses (excluding non-cash stock-based compensation expense and depreciation expense), with a goal of achieving reductions of approximately 30% in 2016 and 60% in 2017 as compared to 2015 operating expenses (excluding non-cash stock-based compensation expense and depreciation expense). In 2016, Apricus expects to continue to generate cash from milestone or licensing payments and royalty revenues from its partners’ sales of Vitaros. Apricus will also continue to pursue out-licensing opportunities for Vitaros in Asia. Apricus’ expenditures will include minimal costs for the preparatory Phase 2b clinical development of RayVa, as well as costs for activities associated with supporting the regulatory approval of Vitaros in the U.S. and the commercialization of Vitaros in Europe. Apricus will host a live conference call and webcast today at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a corporate update. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 8654347. The live and archived audio webcast can be accessed through the Investors Relations’ section of the Company’s website at www.apricusbio.com. Please log in approximately five to ten minutes before the event to ensure a timely connection. The archived webcast will be available for 30 days following the live call. Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Canada and certain countries in Europe, Latin America and the Middle East and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. For further information on Apricus, visit http://www.apricusbio.com. *Vitaros® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus’ plans to grow revenues for Vitaros® outside the United States, the timing and significance of the Type B meeting with the FDA, the timing of regulatory submission and approval of Vitaros in the United States, if any; Apricus’ plans for life-cycle development programs for Vitaros; Apricus’ development and partnering plans for RayVa™; Apricus’ plans to pursue out-licensing opportunities for Vitaros in Asia; Apricus’ plans to reduce operating expenses and achieve profitability, including projected 2016 and 2017 cost savings; and Apricus’ strategic objectives, including efforts to regain compliance with NASDAQ listing standards. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the FDA may reject our strategy for addressing the deficiencies from the 2008 Complete Response letter at our meeting in November 2016; the risk that the cost and other negative effects related to the reduction of Apricus’ workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from its workforce reduction and other cost control measures; Apricus’ dependence on its commercial partners to carry out the commercial launch or grow sales of Vitaros in various territories and the potential for delays in the timing of commercial launches in additional countries; competition in the erectile dysfunction market and other markets in which Apricus and its partners operate; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus’ ability to further develop Vitaros, such as delivery device improvements; Apricus' ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; Apricus’ ability to achieve U.S. and EU Orphan Designation for RayVa; the failure to meet NASDAQ continued listing requirements which could result in Apricus’ common stock being delisted from the exchange; Apricus’ ability to retain and attract key personnel; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to remain in compliance with the terms and restrictions under the credit facility; Apricus’ ability to secure an ex-U.S. strategic partner for RayVa and a licensing partner for Vitaros in Asia; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from Apricus.


Mirixa Corporation, a leading healthcare technology and services company offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior vice president of operations and general counsel and Eric Hoessel to vice president of sales. Litsinger joined Mirixa in 2008 after serving as a partner at Sonnenschein Nath and Rosenthal (now Dentons) and a vice president at America Online. She has been serving Mirixa as General Counsel in addition to leading the compliance, privacy, and corporate development teams. Litsinger has also held the role of interim CEO. “Karen’s service to Mirixa has been invaluable in the eight years she has been with our company,” said Frank Harvey, Mirixa’s chief executive officer. “In her new role, Litsinger will continue to handle many of her current responsibilities, as well as expanding into several new operational areas.” Based in the Reston, VA headquarters, Ms. Litsinger is a past president and board member of both the National Capital Region Chapter of the Association of Corporate Counsel and Ayuda, Inc. She holds a J.D. from Georgetown University Law Center and an A.B. from Duke University. Eric Hoessel joined Mirixa in early 2015 as regional vice president focused on western managed care payers. His recent promotion to vice president of sales will allow Hoessel to focus his depth of industry knowledge and expertise on clients nationwide. Hoessel has enjoyed a successful career in both the pharmaceutical and pharmacy sectors; holding positions of increasing responsibility at large and small organizations including Johnson & Johnson, Schwarz Pharma, Ferring Pharmaceuticals and Walgreen’s. “Eric’s diverse background, virtually unmatched in the healthcare industry, makes him a tremendous asset to Mirixa Corporation. With his extensive knowledge of the marketplace, and superior customer relations skills, Eric is a great fit for this new role leading our sales team,” said Harvey. Based outside of Albuquerque, NM, Hoessel holds a B.A. in Psychology/Management from the University of Wisconsin – Whitewater. For more information about Mirixa and the products offered, visit http://www.mirixa.com. Mirixa Corporation is a leading healthcare technology and services company. We identify and connect patients with trusted pharmacists and other healthcare providers for individualized medication counseling. Our innovative technology and services improve patients’ health and reduce costs. For more information, please visit http://www.Mirixa.com.


News Article | November 18, 2016
Site: www.PR.com

SMi Group Reports: (2016.11.16, London, UK): Over 90 senior leaders in parallel trade will meet in London in February 2017 to discuss upcoming trends and share best practices. London, United Kingdom, November 18, 2016 --( Parallel Trade 2017 official website is www.parallel-trade.com/PRcom Dr Rick Greville, Director Wales and Director Distribution & Supply for The Association of the British Pharmaceutical Industry will be speaking on “The European Commission's Falsified Medicines Directive - recent updates.” Dr. Gr0eville will discuss what progress has been made since February 2016 and what the market participants need to know about "product information templates," and much more. Other key topics to be discussed during the 2-day conference are: What will Brexit mean for parallel trade to and from the UK? Parallel Trade 101 - Which factors determine the flow of pharmaceutical products in Europe? Beyond pharmaceutical products – parallel imports of medical devices. The Patient’s perspective. The event programme also features three panel debates on: Shortages; Challenges and opportunities for parallel traders; Technology & new trends; and two exclusive post conference workshops on “Understanding IP and competition law issues in parallel trade” (Hosted by Kathy Osgerby, Associate and Karoline Zwierzynska, Associate, Arnold & Porter (UK) LLP) and “Parallel Trade – Management Strategies” (Hosted by Janice Haigh, Practice Leader, Market Access, Quintiles). For further information please refer to www.parallel-trade.com/PRcom Expert Speakers Line up for 2017 includes: The Association of the British Pharmaceutical Industry (Dr Rick Greville, Director Distribution & Supply), Shire International GmbH (Eric Noehrenberg, Director, Regional Market Access Lead, Latin America), Delfarma (Tomasz Dzitko, President), European Association for Euro-Pharmaceutical Companies (Heinz Kobelt, Director European Affairs), ISPOR (Vladimir Zah, Health Economics Consultant), Abacus Medicine (Flemming Wagner, CEO), IMS Health (Alexey Savin, Principal Russia and CIS), Arnold & Porter (UK) LLP (Kathy Osgerby, Associate, and Karoline Zwierzynska, Associate), Europe Economics (Dermot Glynn, Senior Advisor), European Alliance for Access to Save Medicines (Mike Isles, Executive Director), Research Health (Dr Andrew Stainthorpe, Director Market Access and Managed Entry) and many more. The complete 2-day event programme is available for complimentary download at www.parallel-trade.com/PRcom Latest confirmed attendees include senior representatives from Astellas Pharma, AstraZeneca, Teva UK, Vifor Pharma, Janssen Pharmaceutica NV, Napp Laboratories, Kantar Health, Ferring Pharmaceuticals, LEO Pharma, AstraZeneca Czech Republic, Swedish Orphan Biovitrum AB, Amgen, Novartis Pharmaceuticals, Novartis Turkey, LEO Pharma, Johnson & Johnson, Novo Nordisk Pharma, Daiichi Sankyo Europe GmbH, Sunovion Pharmaceuticals Europe Ltd and many more. Feedback from past attendees of SMi Group’s Parallel Trade: “Interesting conference, generating a good debate from all sides”, “Great conference! Audience very enthusiastic and actively participating in discussions,” “Very good discussing about pricing issues and competition”, “Overall, a very positive experience!,” “The best Parallel Trade conference of the last 5 years!” 11th annual Parallel Trade 6-7 February 2017, Holiday Inn Kensington Forum, London, UK www.parallel-trade.com/PRcom Sponsorship, Exhibition contact: Alia Malick, +44 (0) 207 827 6168, amalick@smi-online.co.uk Delegates/Group contact: Fateja Begum, +44 (0) 207 827 6184, fbegum@smi-online.co.uk Media Contact: jrotar@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, November 18, 2016 --( PR.com )-- With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? SMi’s Parallel Trade conference will be returning to London next February 6th-7th, for its 11th year, to discuss short term and long term concerns of pharma manufacturers, regulators and parallel traders. They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges.Parallel Trade 2017 official website is www.parallel-trade.com/PRcomDr Rick Greville, Director Wales and Director Distribution & Supply for The Association of the British Pharmaceutical Industry will be speaking on “The European Commission's Falsified Medicines Directive - recent updates.” Dr. Gr0eville will discuss what progress has been made since February 2016 and what the market participants need to know about "product information templates," and much more.Other key topics to be discussed during the 2-day conference are: What will Brexit mean for parallel trade to and from the UK? Parallel Trade 101 - Which factors determine the flow of pharmaceutical products in Europe? Beyond pharmaceutical products – parallel imports of medical devices. The Patient’s perspective.The event programme also features three panel debates on: Shortages; Challenges and opportunities for parallel traders; Technology & new trends; and two exclusive post conference workshops on “Understanding IP and competition law issues in parallel trade” (Hosted by Kathy Osgerby, Associate and Karoline Zwierzynska, Associate, Arnold & Porter (UK) LLP) and “Parallel Trade – Management Strategies” (Hosted by Janice Haigh, Practice Leader, Market Access, Quintiles).For further information please refer to www.parallel-trade.com/PRcomExpert Speakers Line up for 2017 includes: The Association of the British Pharmaceutical Industry (Dr Rick Greville, Director Distribution & Supply), Shire International GmbH (Eric Noehrenberg, Director, Regional Market Access Lead, Latin America), Delfarma (Tomasz Dzitko, President), European Association for Euro-Pharmaceutical Companies (Heinz Kobelt, Director European Affairs), ISPOR (Vladimir Zah, Health Economics Consultant), Abacus Medicine (Flemming Wagner, CEO), IMS Health (Alexey Savin, Principal Russia and CIS), Arnold & Porter (UK) LLP (Kathy Osgerby, Associate, and Karoline Zwierzynska, Associate), Europe Economics (Dermot Glynn, Senior Advisor), European Alliance for Access to Save Medicines (Mike Isles, Executive Director), Research Health (Dr Andrew Stainthorpe, Director Market Access and Managed Entry) and many more.The complete 2-day event programme is available for complimentary download at www.parallel-trade.com/PRcomLatest confirmed attendees include senior representatives from Astellas Pharma, AstraZeneca, Teva UK, Vifor Pharma, Janssen Pharmaceutica NV, Napp Laboratories, Kantar Health, Ferring Pharmaceuticals, LEO Pharma, AstraZeneca Czech Republic, Swedish Orphan Biovitrum AB, Amgen, Novartis Pharmaceuticals, Novartis Turkey, LEO Pharma, Johnson & Johnson, Novo Nordisk Pharma, Daiichi Sankyo Europe GmbH, Sunovion Pharmaceuticals Europe Ltd and many more.Feedback from past attendees of SMi Group’s Parallel Trade: “Interesting conference, generating a good debate from all sides”, “Great conference! Audience very enthusiastic and actively participating in discussions,” “Very good discussing about pricing issues and competition”, “Overall, a very positive experience!,” “The best Parallel Trade conference of the last 5 years!”11th annual Parallel Trade6-7 February 2017, Holiday Inn Kensington Forum, London, UKwww.parallel-trade.com/PRcomSponsorship, Exhibition contact: Alia Malick, +44 (0) 207 827 6168, amalick@smi-online.co.ukDelegates/Group contact: Fateja Begum, +44 (0) 207 827 6184, fbegum@smi-online.co.ukMedia Contact: jrotar@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Russia Viscosupplementation Market Expected to Grow at a CAGR of 5.3% During 2016 to 2026 Future Market Insights has announced the addition of the “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026" report to their offering. Valley Cottage, NY, February 26, 2017 --( According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products. Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897 The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026. Top Players in Russia’s Viscosupplementation Market Top three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market. Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Valley Cottage, NY, February 26, 2017 --( PR.com )-- Russia’s healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people’s eating & drink habits, their proactive lifestyles and the country’s harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia’s viscosupplementation market, conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade.According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products.Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026.Top Players in Russia’s Viscosupplementation MarketTop three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market.Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Click here to view the list of recent Press Releases from Future Market Insights


Russia Viscosupplementation Market Expected to Grow at a CAGR of 5.3% During 2016-2026 Future Market Insights has announced the addition of the "Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment 2016-2026" report to their offering. Valley Cottage, NY, February 24, 2017 --( According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products. Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897 The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026. Top Players in Russia’s Viscosupplementation Market Top three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH andTRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market. Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Valley Cottage, NY, February 24, 2017 --( PR.com )-- Russia’s healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people’s eating & drink habits, their proactive lifestyles and the country’s harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia’s viscosupplementation market, conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade.According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products.Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026.Top Players in Russia’s Viscosupplementation MarketTop three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH andTRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market.Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Click here to view the list of recent Press Releases from Future Market Insights


News Article | February 15, 2017
Site: www.prnewswire.co.uk

Russia's healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people's eating & drink habits, their proactive lifestyles and the country's harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia's viscosupplementation market, conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade. According to Future Market Insights' recent report, titled "Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026," nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia's viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia's healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products. The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia's ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026. Preview Analysis on Russia Viscosupplementation Market Segmentation By Product Type - Single Injection, Three Injection, Five Injection Viscosupplementation; By End Use - Hospitals (500+ Bedded, 250-500 Bedded, Less Than 250 Bedded), Ambulatory Surgical Centres, Orthopaedic Clinics: http://www.futuremarketinsights.com/reports/russia-viscosupplementation-market Top three established players in Russia's Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country's viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia's viscosupplementation market. Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.


SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology. Potential benefits of research in this area include a reduction of adverse effects, increased patient adherence to treatment and more convenient dosing. From 2017, a joint R&D centre and programme, named Nanotechnology Innovation

Loading Ferring Pharmaceuticals collaborators
Loading Ferring Pharmaceuticals collaborators